Passa al contenuto
Merck
  • Discovery of Isoquinolinoquinazolinones as a Novel Class of Potent PPARγ Antagonists with Anti-adipogenic Effects.

Discovery of Isoquinolinoquinazolinones as a Novel Class of Potent PPARγ Antagonists with Anti-adipogenic Effects.

Scientific reports (2016-10-04)
Yifeng Jin, Younho Han, Daulat Bikram Khadka, Chao Zhao, Kwang Youl Lee, Won-Jea Cho
ABSTRACT

Conformational change in helix 12 can alter ligand-induced PPARγ activity; based on this reason, isoquinolinoquinazolinones, structural homologs of berberine, were designed and synthesized as PPARγ antagonists. Computational docking and mutational study indicated that isoquinolinoquinazolinones form hydrogen bonds with the Cys285 and Arg288 residues of PPARγ. Furthermore, SPR results demonstrated strong binding affinity of isoquinolinoquinazolinones towards PPARγ. Additionally, biological assays showed that this new series of PPARγ antagonists more strongly inhibit adipocyte differentiation and PPARγ2-induced transcriptional activity than GW9662.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Anti-α-tubulina monoclonale, ascites fluid, clone B-5-1-2
Sigma-Aldrich
Anti-PPAR γ Antibody, isoform 1&2, ascites fluid, clone 1H4, Chemicon®